Aerovate Therapeutics
Hunter Gillies has been developing treatments for patients with pulmonary hypertension for more than two decades. He has designed and executed phase 2 and phase 3 programs for cardiopulmonary diseases resulting in the approval of multiple drugs for pulmonary arterial hypertension. His work helped establish the current dual combination therapy used as the frontline standard of care in PAH.
This person is not in any offices